Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2017
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Intervertebral disc degeneration; Spinal disorders
- Focus Adverse reactions
- Sponsors Bioinova
- 24 Sep 2017 Status changed from recruiting to discontinued.
- 15 Oct 2014 New trial record